References
- Gamelin E , Boisdron-CelleM, DelvaR et al. Long-term weekly treatment of colorectal metastatic cancer with fluorouracil and leucovorin: results of a multicentric prospective trial of fluorouracil dosage optimization by pharmacokinetic monitoring in 152 patients. J. Clin. Oncol. 4 , 1470–1478 (1998).
- Thyss A , MilanoG, RenéeN, VallicioniJ, SchneiderM, DemardF. Clinical pharmacokinetic study of 5-FU in continuous 5-day infusions for head and neck cancer. Cancer Chemother. Pharmacol.16(1) , 64–66 (1986).
- Santini J , MilanoG, ThyssA et al. 5-FU therapeutic monitoring with dose adjustment leads to an improved therapeutic index in head and neck cancer. Br. J. Cancer 59(2) , 287–290 (1989).
- Hillcoat BL , McCullochPB, FigueredoAT et al. Clinical response and plasma levels of 5-fluorouracil in patients with colonic cancer treated by drug infusion. Br. J. Cancer 38 , 719–724 (1978).
- van Groeningen CJ , PinedoHM, HeddesJ et al. Pharmacokinetics of 5-fluorouracil assessed with a sensitive mass spectrometric method in patients on a dose escalation schedule. Cancer Res. 48(23) , 6956–6961 (1988).
- Gamelin EC , Danquechin-DorvalEM, DumesnilYF et al. Relationship between 5-fluorouracil (5-FU) dose intensity and therapeutic response in patients with advanced colorectal cancer receiving infusional therapy containing 5-FU. Cancer 77(3) , 441–451 (1996).
- Trump DL , EgorinMJ, ForrestA, WillsonJK, RemickS, TutschKD. Pharmacokinetic and pharmacodynamic analysis of fluorouracil during 72-hour continuous infusion with and without dipyridamole. J. Clin. Oncol.9(11) , 2027–2035 (1991).
- de Gramont A , BossetJF, MilanC et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J. Clin. Oncol. 15(2) , 808–815 (1997).
- Capitain O , AsevoaiaA, Boisdron-CelleM, PoirierAL, MorelA, GamelinE. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a Phase II, proof-of-concept study. Clin. Colorectal Cancer. doi:10.1016/j.clcc.2012.05.004 (2012) (Epub ahead of print).
- Ychou M , DuffourJ, KramarA et al. Individual 5-FU dose adaptation in metastatic colorectal cancer: results of a Phase II study using a bimonthly pharmacokinetically intensified LV5FU2 regimen. Cancer Chemother. Pharmacol. 52(4) , 282–290 (2003).
- Gamelin E , DelvaR, JacobJ et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J. Clin. Oncol. 26(13) , 2099–2105 (2008).
- Capitain O , MetgesJ, AdenisA et al. Pharmacokinetic and pharmacogenetic approach to improve dose intensity and tolerance of FOLFIRI + cetuximab in patients with metastatic CRC. Presented at: 2010 Gastrointestinal Cancers Symposium. Orlando, FL, USA, 22–24 January 2010 (Abstract 364).
- Murphy RF , BalisFM, PoplackDG. Stability of 5-fluorouracil in whole blood and plasma. Clin. Chem.33(12) , 2299–2300 (1987).
- Gamelin E , Boisdron-CelleM, TurcantA, LarraF, AllainP, RobertJ. Rapid and sensitive high-performance liquid chromatographic analysis of halogenopyrimidines in plasma. J. Chromatogr. B Biomed. Sci. Appl.695(2) , 409–416 (1997).
- Beumer JH , Boisdron-CelleM, ClarkeW et al. Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzer. Ther. Drug. Monit. 31(6) , 688–694 (2009).